VedaBio Analysis
What is VedaBio?
VedaBio develops the CRISPR Cascade molecular detection platform for ultra-rapid detection of highly multiplexed analytes. The platform uses target amplification-free chemistry and supports rapid reprogramming for new targets. The company says it launched with over 40 million dollars and later announced a strategic agreement with Siemens Healthineers.
Location
11125 Flintkote Ave, San Diego, California 92121, United States
Employees
11-50
Founded
2021
Product Features & Capabilities
- Ultra-rapid molecular detection, CRISPR Cascade™ platform, target amplification-free detection, massive multiplexing capability, rapid reprogramming for new targets.
Who are the founders of VedaBio
AG
Anurup Ganguli
Founder
Investors
- OMX Ventures (lead investor)
- Other undisclosed investors contributing to the initial funding of over $40 million
Market Focus
VedaBio primarily focuses on the biotechnology industry, specifically in the area of molecular detection using its CRISPR Cascade™ platform for accurate detection of multiple analytes.
Business Model
Funding through investments; revenue from molecular detection services and technology licensing.
Competitors Overview
VedaBio operates in the biotechnology sector, focusing on ultra-rapid molecular detection through its CRISPR Cascade™ platform. Its main competitors include:
-
Sherlock Biosciences: This company utilizes CRISPR technology to develop rapid and accurate diagnostic tests for various applications, including healthcare and industrial settings. Their platform is designed for multi-platform testing solutions, which may offer broader application versatility compared to VedaBio's specific focus on molecular detection.
-
Synthego: Known for its CRISPR-based solutions, Synthego provides tools and services for genome engineering. While they focus more on gene editing, their advancements in CRISPR technology could overlap with molecular detection applications, potentially providing a competitive edge in terms of technology integration.
-
Caribou Biosciences: This company is a pioneer in CRISPR technology and focuses on developing therapies and tools for genetic engineering. Their extensive research and development capabilities may provide them with advantages in innovation and application breadth.
-
Intellia Therapeutics: While primarily focused on therapeutic applications of CRISPR, Intellia's advancements in CRISPR technology could influence the molecular detection space, especially if they pivot towards diagnostics.
-
Editas Medicine: Similar to Intellia, Editas is focused on gene editing but has the potential to expand into diagnostics, leveraging their CRISPR technology.
Notable differences and advantages of VedaBio include its specific focus on ultra-rapid molecular detection without the need for target amplification, which may provide faster results compared to traditional methods used by competitors.
See something that needs updating? Suggest edits to this profile.